Doctors Revision

Antifibrinolytic Drugs: Tranexamic Acid, Uses, Safety & Clinical Monitoring

Text size
On this page

1. Fibrinolysis and the drug target

Once a fibrin clot has stopped bleeding, fibrinolysis removes it: tPA (and urokinase) convert plasminogen to plasmin, and plasmin digests fibrin (and, if unchecked, fibrinogen). This is normally protective. When fibrinolysis is premature or excessive — trauma, childbirth, surgery — bleeding worsens and an antifibrinolytic can stabilise the clot.

Scroll the table sideways on a smaller screen.

The fibrinolytic system and where drugs act
ComponentFunctionDrug relevance
tPA / uPAConvert plasminogen → plasmin on the fibrin surfaceLysine analogues (TXA, aminocaproic acid) competitively block plasminogen's lysine-binding site so it cannot attach to fibrin
PlasminDegrades fibrin (clot dissolution)Blockade preserves clot stability
α₂-antiplasmin, PAI-1Natural brakes on fibrinolysisAntifibrinolytics reinforce this brake; excessive inhibition tips toward thrombosis
Thrombolytics (streptokinase, alteplase)Accelerate plasmin generation to dissolve pathological clotsThe opposite therapeutic direction — never confuse the two classes

2. Classification and pharmacology

Scroll the table sideways on a smaller screen.

Classification of antifibrinolytics
DrugMechanismNotes
Tranexamic acid (TXA)Synthetic lysine analogue; competitively blocks lysine-binding sites on plasminogen/plasmin, preventing fibrin binding and plasmin formationMain agent in use; oral, IV and topical routes
Aminocaproic acidLysine analogue with similar inhibitionSpecialist perioperative/haematology use; e.g., 4–5 g IV load then 1 g/hour infusion in protocols
AprotininSerine-protease inhibitor (inhibits plasmin directly)Restricted use (cardiac surgery); hypersensitivity and safety concerns limit it

3. Tranexamic acid in detail

Scroll the table sideways on a smaller screen.

Tranexamic acid pharmacology
AspectDetail
Adult dosing (indication-specific)PPH: 1 g IV over 10 min as soon as possible (within 3 h of birth), then 1 g IV over 8 h if bleeding continues. Trauma (CRASH-2): 1 g over 10 min within 3 h of injury, then 1 g over 8 h. Heavy menstrual bleeding: 1 g orally TDS–QDS (up to 4 days/cycle). Surgery: per protocol, often 1 g IV pre-incision. Topical (mouthwash 4.8–5%) for oral bleeding/dental extraction in anticoagulated patients.
Paediatric dosingSpecialist-protocol only; common teaching range 15–30 mg/kg IV loading (max 1 g) then maintenance per protocol. Never extrapolate adult emergency doses without senior direction.
PharmacokineticsRapid renal excretion, mostly unchanged — half-life rises sharply in renal impairment → dose-adjust by protocol; crosses placenta and appears in breast milk in small amounts (compatible with breastfeeding).
IndicationsPPH (WHO-recommended); trauma with significant bleeding; surgical blood-loss reduction; heavy menstrual bleeding (non-hormonal option); dental/mucosal bleeding adjunct in haemophilia; epistaxis topical.
Adverse effectsNausea, vomiting, diarrhoea, dizziness, headache; rapid IV push → hypotension; colour-vision disturbance; seizures reported with high-dose IV use (neurosurgical/cardiac settings); thrombosis risk if misused.
ContraindicationsActive thromboembolic disease (DVT/PE/arterial thrombus); acquired defective colour vision (for prolonged use); subarachnoid haemorrhage (cerebral oedema/ischaemia risk — older concern); undifferentiated upper-urinary-tract haematuria (risk of clot colic/obstruction); severe renal impairment without dose adjustment; known hypersensitivity. Caution: prior thrombosis history, combined hormonal contraceptive use (additive thrombosis risk — for non-emergency indications review together).
InteractionsAdditive pro-thrombotic effect with oestrogen-containing contraceptives or thrombogenic medicines — relevant for elective (non-emergency) prescribing; minimal CYP interactions (renally cleared, low protein binding).
CounsellingFor heavy periods: take only during menstruation; reduces bleeding but does not treat the cause — keep review appointments, check iron/ferritin; report leg swelling, chest pain, breathlessness, visual changes immediately; seek urgent care for uncontrolled bleeding.

4. Indications and dosing

Scroll the table sideways on a smaller screen.

Indication → dose → rule
SituationTypical regimenClinical rule
Postpartum haemorrhage1 g IV over 10 min (within 3 h), then 1 g over 8 h if neededAlongside uterine massage, uterotonics, fluids, source control — never instead of them
Major traumaSame 1 g + 1 g over 8 h regimen, within 3 h of injuryRecord injury time; adjunct to ABCDE, blood products, surgery
Surgery1 g IV pre-incision (protocol-dependent)Review thrombosis history and renal function first
Heavy menstrual bleeding1 g PO TDS–QDS during menses, max 4 days/cycleAssess cause, check iron; review CHC/thrombosis risk
Dental/mucosal bleeding (haemophilia, anticoagulation)Topical 4.8–5% mouthwash; systemic per haematology protocolAdjunct to factor replacement and local measures
EpistaxisTopical (soaked pledget) as adjunctPressure and packing remain first-line

4.1 Where TXA sits in the major-haemorrhage bundle

TXA never acts alone. A structured major-haemorrhage response typically runs:

  1. Call for help early — activate the emergency/major-haemorrhage pathway.
  2. Airway, breathing, circulation — two wide-bore cannulas, bloods (FBC, clotting, fibrinogen, crossmatch), begin balanced transfusion per protocol.
  3. TXA early — 1 g over 10 min then 1 g over 8 h (within 3 h windows for trauma/PPH).
  4. Source control — surgery, interventional radiology, packing, uterotonics as appropriate.
  5. Correct the lethal triad — hypothermia, acidosis, coagulopathy: warm the patient, correct Ca²⁺, replace fibrinogen (cryoprecipitate/fibrinogen concentrate per protocol).
  6. Monitor and reassess — physiological response, ongoing losses, urine output; escalate if the trajectory is not improving.

4.2 Dental example — anticoagulated patient needing extraction

A patient on warfarin (INR in range) needs a tooth extraction with a history of post-extraction bleeding. The haematology/dental protocol commonly combines: local measures first (atraumatic technique, sutures, haemostatic gauze, pressure), topical TXA mouthwash (4.8–5%) used 4×/day for several days, and only where bleeding risk is high, systemic TXA — while continuing monitoring of the INR. The lesson: antifibrinolytics are adjuncts layered onto local haemostasis, not replacements for it.

5. Safety, contraindications and monitoring

  • Pre-treatment checklist: source and mechanism of bleeding; time of onset (PPH/trauma windows); thrombosis history and thrombophilia; seizure history; renal function; anticoagulants/antiplatelets; pregnancy/breastfeeding for elective use.
  • Monitor during acute use: pulse, BP, ongoing losses, urine output, mental state, response to definitive treatment; trend FBC, coagulation/fibrinogen and renal function per major-haemorrhage protocol. A single lab value does not prove haemostasis.
  • Administration: give IV TXA at the prescribed rate (over ~10 min) — rapid push causes hypotension.
  • Escalate immediately for: chest pain, dyspnoea, new unilateral leg swelling, focal neurology, visual disturbance, or persistent/severe bleeding.

6. Worked scenarios

Scenario A — PPH: 40 minutes after a vaginal delivery, a mother bleeds heavily with a relaxed uterus. Call for help; rub up a contraction; give oxytocin; 1 g TXA IV over 10 min; two large-bore IV lines, fluids; examine for tears/retained placenta; continue 1 g over 8 h if bleeding persists; escalate to balloon tamponade/theatre as needed. TXA is one element of a bundle — speed matters.

Scenario B — trauma: a boda-boda rider, GCS 14, BP 90/60, 90 minutes after a crash. Activate major haemorrhage pathway: ABCDE, two wide-bore cannulas, bloods including crossmatch, 1 g TXA over 10 min then 1 g over 8 h (within the 3-hour window), tranexamic timing documented, damage-control surgery referral.

Scenario C — heavy periods with prior PE: 34-year-old requests TXA for heavy menses; history of unprovoked PE on anticoagulation 3 years ago. Do not prescribe casually: assess thrombosis risk, review CHC use, consider alternatives (levonorgestrel IUD, hormonal therapy); if TXA is used, specialist review and the lowest effective dose with clear safety-netting.

7. Key points

References

  • WOMAN Trial Collaborators. "Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage." Lancet 2017. (Library reference.)
  • CRASH-2 Trial Collaborators. "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients." Lancet 2010. (Library reference.)
  • WHO — recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017 update). (Library reference.)
  • NICE NG88 — Heavy menstrual bleeding: assessment and management. (Library reference.)

For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top